News from stealth biotherapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jul 02, 2019, 08:00 ET Stealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial Disorders

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...


May 30, 2019, 08:00 ET Stealth Biotherapeutics to Present at Upcoming Investor Conferences

Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...


May 15, 2019, 16:05 ET Stealth BioTherapeutics Reports First Quarter 2019 Financial Results And Recent Business Highlights

Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...


May 14, 2019, 16:15 ET Stealth BioTherapeutics to Present at UBS Global Healthcare Conference

Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...


Apr 30, 2019, 16:23 ET Stealth BioTherapeutics Announces Positive Results for Elamipretide in Ophthalmic Conditions

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...


Apr 25, 2019, 16:15 ET Stealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial Myopathy

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...


Apr 16, 2019, 18:01 ET Stealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension Trial

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...


Apr 04, 2019, 19:35 ET Stealth BioTherapeutics Reports Fiscal Year 2018 Financial Results and Recent Business Highlights

Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...


Apr 02, 2019, 08:00 ET Stealth BioTherapeutics to Present at H.C. Wainwright Global Life Sciences Conference

Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...


Mar 28, 2019, 08:06 ET Stealth BioTherapeutics Announces Dosing Of First Patient In Phase 2 Study Of Elamipretide For The Treatment Of Dry AMD

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...


Mar 04, 2019, 16:12 ET Stealth BioTherapeutics Announces Partial Exercise and Closing of Over-Allotment Option

Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...


Feb 14, 2019, 22:45 ET Stealth BioTherapeutics Announces Pricing of Initial Public Offering

Stealth BioTherapeutics (Stealth), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...


Dec 10, 2018, 09:00 ET Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Dry Age-Related Macular Degeneration with Geographic Atrophy

Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today...


Aug 14, 2018, 09:00 ET Stealth BioTherapeutics Expands Pipeline, Advances New Compound

Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing a first-in-class platform of novel therapeutic compounds for ...


Jun 18, 2018, 09:00 ET Stealth BioTherapeutics Announces $100M Financings to Advance Clinical Development of Elamipretide and Pipeline

Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing a first-in-class platform of novel therapeutic compounds for the...


Mar 06, 2018, 09:00 ET Stealth BioTherapeutics Completes Enrollment of Study for the Treatment of Barth Syndrome

Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational therapeutics to treat mitochondrial...


Dec 18, 2017, 08:00 ET Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Leber's Hereditary Optic Neuropathy

Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today...


Nov 27, 2017, 08:00 ET Stealth BioTherapeutics Granted Fast Track Designation for the Treatment of Barth Syndrome

Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today...


Nov 06, 2017, 08:00 ET Stealth BioTherapeutics Initiates Phase 3 Study of Elamipretide in Patients with Primary Mitochondrial Myopathy

Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today...


Oct 02, 2017, 09:00 ET Stealth BioTherapeutics Granted Orphan Drug Designation of Elamipretide for Treatment of Patients with Primary Mitochondrial Myopathy

Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today...


Aug 07, 2017, 09:00 ET Stealth BioTherapeutics Announces New Appointments to its Board of Directors

Stealth BioTherapeutics Inc. (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction,...


Jul 24, 2017, 09:00 ET Stealth BioTherapeutics Initiates Phase 2/3 Study of Elamipretide in Patients With Barth Syndrome

Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today...


Jun 29, 2017, 11:30 ET Stealth BioTherapeutics Presents Phase 2 Data From MMPOWER-2 Continuation Trial Supporting Phase 3 Development of Elamipretide in Primary Mitochondrial Myopathy

Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today...


Jun 15, 2017, 09:00 ET Stealth BioTherapeutics to Present Top-Line Data From MMPOWER-2 Phase 2 Continuation Trial at Mitochondrial Medicine Symposium 2017

Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today...


May 02, 2017, 09:00 ET Stealth BioTherapeutics Initiates Phase 1/2 Trial of SBT-20 in Patients With Early Stage Huntington's Disease

Stealth BioTherapeutics Inc. (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today...